• LAST PRICE
    0.5050
  • TODAY'S CHANGE (%)
    Trending Down-0.0310 (-5.7836%)
  • Bid / Lots
    0.5010/ 1
  • Ask / Lots
    0.5186/ 13
  • Open / Previous Close
    0.5400 / 0.5360
  • Day Range
    Low 0.5000
    High 0.5613
  • 52 Week Range
    Low 0.4510
    High 1.7900
  • Volume
    400,277
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.536
TimeVolumePASG
09:32 ET3230.54
09:35 ET5500.53
09:44 ET11000.53
09:46 ET1850.5399
09:51 ET1000.5269
09:57 ET21000.52
10:00 ET1000.52
10:13 ET20000.530001
10:15 ET1000.52
10:20 ET1000.5378
10:29 ET3450.530599
10:33 ET1000.5212
10:40 ET1000.54
10:42 ET1000.5212
10:45 ET14000.520695
10:47 ET1000.54
10:49 ET5200.5205
10:51 ET1000.5205
10:56 ET1000.54
11:02 ET7000.530251
11:03 ET1000.54
11:07 ET4600.54
11:12 ET4500.5352
11:18 ET1300.54
11:30 ET3050.532501
11:34 ET2000.5365
11:36 ET11000.5399
11:41 ET10000.5377
11:43 ET66160.5404
11:45 ET1100.55
11:56 ET12500.54
11:57 ET10000.54125
12:01 ET16500.5499
12:03 ET11840.55
12:14 ET50000.5613
12:17 ET51000.5558
12:21 ET3810.5558
12:26 ET72880.5442
12:39 ET22340.5393
12:42 ET1500.5505
12:46 ET8940.541501
12:48 ET34330.5415
12:50 ET96000.5325
12:53 ET89500.5325
12:57 ET57000.521
01:02 ET88770.5201
01:09 ET38000.5201
01:11 ET115410.514
01:13 ET11530.5115
01:22 ET1500.521
01:26 ET1000.512
01:29 ET24100.512
01:31 ET13840.512
01:33 ET2500.5299
01:36 ET32000.52
01:38 ET103550.511
01:40 ET20000.5205
01:42 ET160470.5101
01:44 ET53590.5
01:45 ET14000.5
01:47 ET109000.5001
01:49 ET185750.5
01:51 ET52500.508601
01:54 ET15960.5086
01:58 ET43820.5001
02:00 ET12500.5002
02:02 ET28350.51
02:12 ET5000.5111
02:16 ET10000.5171
02:18 ET5800.5151
02:21 ET86840.516
02:23 ET85850.519
02:25 ET238750.51
02:27 ET57940.5
02:30 ET1000.5006
02:32 ET2000.5005
02:34 ET54240.5105
02:36 ET6500.504
02:38 ET50000.5028
02:39 ET48500.5027
02:41 ET10000.5006
02:43 ET4160.5005
02:45 ET1000.5006
02:48 ET20000.505
02:50 ET24000.5006
02:52 ET4500.5005
02:54 ET2000.5005
02:56 ET1000.5005
02:57 ET27000.5005
02:59 ET3000.5005
03:01 ET1000.5005
03:03 ET16730.5005
03:06 ET293130.5103
03:08 ET2180.5012
03:12 ET2300.5005
03:14 ET5190.5005
03:17 ET10000.5161
03:19 ET43000.5005
03:21 ET1000.5005
03:24 ET15000.5005
03:26 ET14000.5005
03:28 ET1000.5005
03:30 ET12000.5005
03:32 ET318000.5005
03:35 ET60670.5005
03:37 ET10000.5005
03:39 ET12970.5005
03:42 ET7400.5005
03:44 ET11340.505
03:46 ET2000.5051
03:50 ET8000.51
03:51 ET1000.5051
03:53 ET10000.5132
03:57 ET1000.505
04:00 ET152920.505
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPASG
Passage Bio Inc
31.2M
-0.4x
---
United StatesRNXT
RenovoRx Inc
30.9M
-2.3x
---
United StatesALTS
ALT5 Sigma Corp
30.8M
-0.6x
---
United StatesCMMB
Chemomab Therapeutics Ltd
30.5M
-1.7x
---
United StatesCERO
CERo Therapeutics Holdings Inc
32.2M
-0.6x
---
United StatesLIANY
LianBio
32.2M
-0.4x
---
As of 2024-11-23

Company Information

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Contact Information

Headquarters
One Commerce Square 2005 Market Street, 39Th FloorPHILADELPHIA, PA, United States 19103
Phone
267-866-0312
Fax
302-655-5049

Executives

Independent Chairwoman of the Board
Maxine Gowen
President, Chief Executive Officer, Director
William Chou
Chief Financial Officer
Kathleen Borthwick
Chief Scientific Officer
Susan Browne
General Counsel, Company Secretary
Edgar Cale

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$31.2M
Revenue (TTM)
$0.00
Shares Outstanding
61.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.16
EPS
$-1.17
Book Value
$2.03
P/E Ratio
-0.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.